Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 2 , Pages 155-160 , March 2012

Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians

  • Gregory E. Tasian, M.D., M.Sc.

      Affiliations

    • Department of Urology, University of California, San Francisco, CA 94143, USA
    • ,
  • Matthew R. Cooperberg, M.D., M.P.H.

      Affiliations

    • Department of Urology, University of California, San Francisco, CA 94143, USA
    • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA
    • ,
  • Janet E. Cowan, M.A.

      Affiliations

    • Department of Urology, University of California, San Francisco, CA 94143, USA
    • ,
  • Kian Keyashian, M.D.

      Affiliations

    • Department of Internal Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • Conducted work while at the University of California, San Francisco Medical School.
    • ,
  • Kirsten L. Greene, M.D., M.S.

      Affiliations

    • Department of Urology, University of California, San Francisco, CA 94143, USA
    • ,
  • Nicholas A. Daniels, M.D., M.P.H.

      Affiliations

    • Department of Internal Medicine, Division of General Internal Medicine, University of California, San Francisco, CA 94158, USA
    • ,
  • Peter R. Carroll, M.D., M.P.H.

      Affiliations

    • Department of Urology, University of California, San Francisco, CA 94143, USA
    • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA
    • ,
  • June M. Chan, Sc.D.

      Affiliations

    • Department of Urology, University of California, San Francisco, CA 94143, USA
    • Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-415-514-4923; fax: +1-415-514-4927

Received 19 November 2009 ,Revised 19 December 2009 ,Accepted 22 December 2009.

References 

  1. Jemal A , Siegel R , Ward E , et al.  Cancer statistics, 2009 . CA Cancer J Clin . 2009;59:225–249
  2. Messing EM , Manola J , Sarosdy M , et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer . N Engl J Med . 1999;341:1781–1788
  3. Potosky AL , Feuer EJ , Levin DL . Impact of screening on incidence and mortality of prostate cancer in the United States . Epidemiol Rev . 2001;23:181–186
  4. Albertsen PC , Fryback DG , Storer BE , et al.  Long-term survival among men with conservatively treated localized prostate cancer . JAMA . 1995;274:626–631
  5. Klotz L . Active surveillance with selective delayed intervention for favorable risk prostate cancer . Urol Oncol . 2006;24:46–50
  6. Smith RA , Cokkinides V , Brawley OW . Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening . CA Cancer J Clin . 2009;59:27–41
  7. Scardino P . Update: NCCN prostate cancer Clinical Practice Guidelines . J Natl Compr Canc Netw . 2005;3(Suppl 1):S29–S33
  8. Lin K , Lipsitz R , Miller T , et al.  Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force . Ann Intern Med . 2008;149:192–199
  9. Ferrini R , Woolf SH . American College of Preventive Medicine practice policy (Screening for prostate cancer in American men) . Am J Prev Med . 1998;15:81–84
  10. Kim HL , Benson DA , Stern SD , et al.  Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey . Urology . 2002;59:266–271
  11. Thompson IM , Pauler DK , Goodman PJ , et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter . N Engl J Med . 2004;350:2239–2246
  12. Hoffman RM , Couper MP , Zikmund-Fisher BJ , et al.  Prostate cancer screening decisions: Results from the National Survey of Medical Decisions (DECISIONS study) . Arch Intern Med . 2009;169:1611–1618
  13. Hoffman RM , Papenfuss MR , Buller DB , et al.  Attitudes and practices of primary care physicians for prostate cancer screening . Am J Prev Med . 1996;12:277–281
  14. Edlefsen KL , Mandelson MT , McIntosh MW , et al.  Prostate-specific antigen for prostate cancer screening (Do physician characteristics affect its use?) . Am J Prev Med . 1999;17:87–90
  15. Moran WP , Cohen SJ , Preisser JS , et al.  Factors influencing use of the prostate-specific antigen screening test in primary care . Am J Manag Care . 2000;6:315–324
  16. Stroud L , Ross LE , Rose SW . Formative evaluation of the prostate cancer screening practices of African-American physicians . J Natl Med Assoc . 2006;98:1637–1643
  17. Purvis-Cooper C , Merritt TL , Ross LE , et al.  To screen or not to screen, when clinical guidelines disagree: Primary care physicians' use of the PSA test . Prev Med . 2004;38:182–191
  18. Austin OJ , Valente S , Hasse LA , et al.  Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians . Arch Fam Med . 1997;6:453–458
  19. U.S. Preventive Services Task Force . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement . Ann Intern Med . 2008;149:185–191
  20. Schroder FH , Hugosson J , Roobol MJ , et al.  Screening and prostate-cancer mortality in a randomized European study . N Engl J Med . 2009;360:1320–1328
  21. Andriole GL , Crawford ED , Grubb RL , et al.  Mortality results from a randomized prostate-cancer screening trial . N Engl J Med . 2009;360:1310–1319

PII: S1078-1439(09)00429-3

doi: 10.1016/j.urolonc.2009.12.019

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 2 , Pages 155-160 , March 2012

Article Tools

* Image Usage & Resolution